Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967888 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
A Phase 2 study, sponsored by Dompé Farmaceutici S.p.A.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT01967888 is a Phase 2 study that has completed, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 104 participants.
The verdict
NCT01967888, a Phase 2 study, has completed, sponsored by Dompé Farmaceutici S.p.A.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
The study is a phase 2/3, multicenter, double-blind, parallel assignment study. It involves 100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT). The objective of this clinical trial is to assess whether reparixin leads to improved transplant outcome as measured by the proportion of insulin-independent patients following IAT. The safety of reparixin in the specific clinical setting will be also evaluated.
Interventions
- DRUG Placebo
- DRUG Reparixin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01967888
The ClinicalTrials.gov registry entry for NCT01967888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01967888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01967888 about?
NCT01967888 is a clinical study titled "Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation". The study is a phase 2/3, multicenter, double-blind, parallel assignment study. It involves 100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT). The objective of this clinical trial is to assess whether reparixin leads to improved transplant outcome as measured by t...
What is the current status of trial NCT01967888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2014-02. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01967888?
The interventions under investigation include: Placebo (DRUG), Reparixin (DRUG).
Who is sponsoring clinical trial NCT01967888?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.